Introduction
Intravenous immunoglobulin (IVIg) has been used for many years as an antibody replacement therapy for patients with primary immunodeficiencies [1, 2] and, since the early 1980s, as a therapy for several autoimmune diseases and inflammatory conditions [3] [4] [5] [6] [7] [8] . High-dose IVIg has been used to treat immune thrombocytopenia (ITP) for more than 30 years; however, the mechanism of IVIg action in ITP and in other autoimmune/inflammatory diseases is currently unresolved [9] [10] [11] [12] [13] [14] [15] .
Several mechanisms of action for the immunomodulatory and anti-inflammatory effects of IVIg have been proposed; however, there remains controversy regarding this subject. Previously proposed mechanisms include FcR blockade [15] , anti-idiotypic antibodies [16] , inhibition of complement [17] , increased regulatory T cell involvement [18, 19] , up-regulation of the inhibitory Fcγ receptor (FcγRIIb) on macrophages 20, modulation of peripheral tolerizing dendritic cells (DCs) [21, 22] and saturation of the neonatal FcR (FcRn) to enhance autoantibody clearance [23, 24] . Most of these have been challenged or even refuted by subsequent publications [25] [26] [27] [28] [29] [30] [31] .
Currently, one model for the mechanism of action of IVIg continues to be discussed, despite the numerous publications that refute this model [32] [33] [34] [35] [36] [37] [38] [39] . In this model, the Fcγ sialylated fraction of IgG is responsible for the antiinflammatory properties of IVIg [32, 35, 37] . The model theorizes that a minor population (~10%) of total IgG sialylated in the Fcγ domain engages the CD209 receptor (DC-SIGN) on regulatory macrophages/dendritic cells, which causes their release of IL-33 [35] [36] [37] [38] [39] . IL-33 is a Th2-polarizing cytokine that further causes basophils to release IL-4 at sites of inflammation. IL-4 acts on macrophages to upregulate the expression of FcγRIIb, which acts further to inhibit the activating Fcγ receptors and dampen the autoimmune response [36] . Indeed, this model proposes that the subsequent increase in expression of FcγRIIb on effector cells raises the threshold of activation for inflammatory effector cells allowing for a reduction in inflammation 20,36. Numerous scientists in the field have not been able to support this model of IVIg action [25] [26] [27] [28] [29] . A previous study where the investigators used interleukin (IL)-4 and common gamma chain-deficient mice indicated that IL-4 was not involved in the mechanism of action of IVIg to ameliorate ITP [40] . However, other studies maintain that IL-4 is a major cytokine, produced by activated basophils, in the mechanism of IVIg action [32] [33] [34] [35] [36] [37] [38] [39] ; thus, whether or not IL-4 plays any role in the mechanism of IVIg action in ITP remains an open question.
Few studies have focused on the cytokines produced in mouse models of ITP with and without treatment with IVIg. A recent report that looked at cytokine/chemokine induction by IVIg, using a multiplex cytokine assay and two different strains of mice with ITP that respond to IVIg, has shown that IL-33 is produced following IVIg treatment only in BALB/cJ mice, but not in C57BL/6J mice [41] . This supports other studies which have shown that IL-33 is not involved in the mechanism of IVIg action [42] . However, high amounts of IL-4 were produced in both mouse strains upon IVIg induction. Despite shown previously that both IL-4 deficient and common cytokine receptor gamma chain-deficient mice respond to IVIg [40] , other published data still support a role for IL-4 and basophils that produce the IL-4 in the mechanism of IVIg action [32] [33] [34] [35] [36] [37] [38] [39] . Thus, a role for IL-4 and basophils requires further study. Interestingly, in addition to IL-4, both IL-11 and granulocyte-macrophage colony-stimulating factor (GM-CSF) were produced significantly following IVIg treatment in both mouse strains, with IL-11 reaching nanogram levels [41] .
The work reported herein investigates whether any of the cytokines induced by IVIg in both mouse strains could be playing a role in the mechanism of action of IVIg in ITP. Using a murine model of ITP, we confirm a previous report that IL-4 (or basophils) are not involved in the IVIg mechanism in the amelioration of ITP. We show further that GM-CSF is also unnecessary. In contrast, a role for IL-11 cannot be ruled out.
Materials and methods

Mice and reagents
Wild-type (WT) BALB/cJ and C57BL/6J females were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) at 6-8 weeks of age. IL-4 receptor knock-out (IL-4R -/-), GM-CSF knock-out (Csf2 -/-) and IL-11 receptor α-chain knock-out (IL-11Rα -/-) breeding pairs were purchased from The Jackson Laboratory and bred in our animal facility. Genotyping confirmed the knock-outs (data not shown). Mice were kept under a natural light-dark cycle, maintained at 22 ± 4°C, and fed with standard diet and water ad libitum. The use of animals was consistent with the requirements of the Canadian Council on Animal Care (CCAC) and the specific animal use protocol (AUP 829.35) was reviewed and approved by the University Health Network (UHN) Animal Research Committee in Toronto. Typically, three to six mice were used in each experimental and control group of animals. Specific numbers used for each experiment are given in the corresponding figure legends. To justify the minimum number of animals used for each experiment, we calculated the group size (n) required at 80% power and significance level (two-tailed, alpha = 0·05) to observe an effect of expected size using the t-statistic and non-centrality parameter [for comparing two means, effect size (E/S) = k × δ, where t-value at degrees of freedom (d.f.) = n total -2, where n total = n 1 + n 2 , δ is the non-centrality parameter, and k = (1/n 1 + 1/n 2 ) 1/2 ]. For example, we used three animals per group aiming to resolve an effect size of > 3·0 standard deviations and five animals per group where we aimed to resolve an effect size as small as 2·0 standard deviations. In some control (baseline) groups, to minimize the number of animals used, where standard deviation was expected to be smaller based on previous observations, a smaller n = 3 group size was used to achieve the desired statistical power of 80%.
The rat monoclonal anti-mouse glycoprotein IIb (CD41; clone MWReg30, rat IgG1λ) antibody used to induce ITP was purchased from BD PharMingen (Mississauga, ON, Canada). The IVIg preparation Gamunex 10% used to treat ITP was purchased from Talecris Biotherapeutics (Research Triangle Park, NC, USA). Privigen 10% IVIg was from CSL Behring (Bern, Switzerland). The Armenian hamster monoclonal anti-mouse Fc epsilon receptor I alpha (FcεR1) (MAR-1; hamster IgG) antibody used to deplete basophils in vivo was purchased from eBioscience (San Diego, CA, USA). The rhIL-11 protein used to treat ITP was purchase from R&D Systems, Inc. (Minneapolis, MN, USA). The rat monoclonal anti-mouse IL-11 (clone 188520, rat IgG2a) antibody used to neutralize mouse IL-11and the goat immunoglobulin (Ig)G were purchased from R&D Systems, Inc.
ITP mouse model
A dose-escalation mouse model of passive platelet (PLT) antibody (MWReg30)-induced ITP was used, as described previously 43. Briefly, mice were injected with 68 μg/kg of MWReg30 on days 0 and 1, followed by increasing doses of an additional 34 μg/kg on each subsequent day. It has been well established that, under these conditions, PLT nadir is achieved on day 2 and maintained until day 5 41,43,44. Platelets in whole blood samples were quantified daily using a calibrated flow cytometer [fluorescence activated cell sorter (FACS)Calibur; Becton Dickinson, Franklin Lakes, NJ, USA] as described previously [43] . For treatment of ITP, IVIg was given intraperitoneally (i.p.) 2h after PLT antibody administration on day 2 of the experiment at 1-2 g/kg for BALB/cJ or IL-4R -/-mice or at 2-2·5g/kg for C57BL/6J or IL-11Rα -/-or IL-11Rα +/+ or Csf2 -/-mice, as optimized previously [43, 44] . To control for the protein content of IVIg, we used human serum albumin (HSA; Canadian Blood Services, Toronto, ON, Canada) at the same g/kg dose used for IVIg.
In-vivo depletion of basophils in BALB/cJ mice
Basophils were depleted by injection of 5 μg of anti-FcεR1 (MAR-1) twice daily i.p. for 3 consecutive days starting 4 days before ITP induction, as optimized previously [28, 45] . Controls received the same dose of the isotype control (Armenian hamster IgG antibody). Basophil populations were analysed by flow cytometry, using a FACSCalibur, by staining monocytes/granulocytes in the peripheral blood with anti-CD49b-phycoerythrin (PE) (5 μg/ml) and CD123-allophycocyanin (APC) (5 μg/ml) antibodies (eBioscience).
Treatment of ITP with recombinant human IL-11
For treatment of ITP, rhIL-11 was given i.p. 2h after PLT antibody administration on day 2 of the experiment at 10-12 µg/mouse for BALB/cJ mice. This was compared to treatment with IVIg given to BALB/cJ mice in a separate treatment group with similar conditions at 1g/kg.
Neutralizing antibody to mouse IL-11
To neutralize IL-11 and for treatment of ITP, both antimouse IL-11 antibody and IVIg were given with a 30-min interval i.p. 2h after PLT antibody administration on day 2 of the experiment at 100 µg/mouse (5mg/kg) and 1g/kg, respectively, using BALB/cJ mice. To control for the added IgG from the neutralizing antibody, when given with the IVIg, goat IgG was injected at 5 mg/kg along with the IVIg as a non-neutralizing control.
Flow cytometric analysis
To quantify basophil numbers in peripheral blood, singlecell suspensions of red blood cell (RBC)-depleted peripheral blood were resuspended in phosphate-buffered saline (PBS) containing 1% (w/v) bovine serum albumin (BSA). Cells (~1 × 10 6 ) were stained with APC-conjugated anti-CD123 (5B11; eBioscience) and PE-conjugated anti-CD49b monoclonal antibody (mAb) (DX5; BD Pharmingen). Propidium iodide (1 μg/ml; Sigma-Aldrich, St Louis, MO, USA) was used to exclude dead cells, and live cells were analysed on a BD LSR II (BD Biosciences) using FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Statistical analysis
All statistical analyses were performed using GraphPad Prism version 6.0 (GraphPad Inc., San Diego, CA). Significant differences between experimental groups was determined using a two-tailed Student's t-test and P-values of less than 0·05 were regarded as significant. All experiments were designed to have at least 80% power (beta of 0·2) to detect the desired effect size. The group comparisons for statistical analysis were as follows: (1) 
Results
Basophils and IL-4 are not required for IVIg amelioration of ITP
We had previously quantified cytokine serum levels in BALB/cJ (and C57BL/6J) mice following IVIg treatment in a murine model of ITP and found IL-4, among others, to be elevated significantly 41. Although a previous report using IL-4 and common cytokine gamma chain knock-out mice 40 suggested that IL-4 does not play a significant role in the mechanism of IVIg amelioration of ITP, other groups have claimed that IL-4 produced by basophils is a main player in the IVIg mechanism [32] [33] [34] [35] [36] [37] [38] [39] . Thus, based on our cytokine results showing increased IL-4 following IVIg treatment, we investigated the role of IL-4 and basophils in the ability of IVIg to ameliorate ITP. To investigate a role for IL-4, we approached this in two ways: (i) we used an IL-4 receptor knock-out mouse instead of an IL-4 knock-out mouse, as in previous work [40] , and (ii) we examined a role for basophils in our ITP mouse model. Given that previous reports showed that basophils play no role in the mechanism of IVIg action in mouse arthritis models [28] , we expected to find that basophils were not involved in the mechanism of IVIg action in our murine mouse models of ITP; however, this has never been examined.
First, we showed that BALB/cJ mice were depleted successfully of basophils in vivo using a MAR-1 antibody (Fig. 1a) . Next, we induced ITP in these mice that were essentially devoid of basophils and examined whether they responded differently to IVIg treatment than WT BALB/cJ mice. We found that neither ITP induction nor its amelioration by IVIg depends on basophils, as these mice responded similarly to IVIg treatment, as did WT BALB/cJ mice (Fig. 1b) . In addition to basophils being disposable in the mechanism of IVIg action, we showed that IL-4 was not required. We achieved this by inducing ITP in IL-4 receptor knock-out (IL-4R -/-) BALB/cJ mice and examining whether these mice responded differently to IVIg treatment than WT BALB/cJ mice. We found that neither ITP induction nor its amelioration by IVIg depends upon IL-4, as the IL-4R -/-mice responded similarly to IVIg treatment as the WT BALB/cJ mice (Fig. 1c) .
GM-CSF is not required for IVIg amelioration of ITP
In addition to showing that IL-4 was elevated in BALB/cJ and C57BL/6J mice following IVIg treatment in a murine model of ITP, we also showed that GM-CSF was elevated [40]. Because there has been little attention given to this cytokine in the mechanism of action of IVIg in ITP, we were curious as to whether this cytokine played a role. We induced ITP in Csf2 -/-C57BL/6J GM-CSF knock-out mice and examined whether they responded differently to IVIg treatment in comparison to C57BL/6J WT mice. In accordance with our previous results with basophils and IL-4, we found that neither ITP induction nor its amelioration by IVIg depends upon GM-CSF, as the Csf2 -/-C57BL/6J knock-out mice responded similarly to IVIg treatment as the C57BL/6J WT mice (Fig. 2) .
IL-11 may be involved in IVIg amelioration of ITP
We have shown previously that IL-11 is greatly elevated in BALB/cJ and C57BL/6J mice following IVIg treatment of ITP [41, 46, 47] . To begin to investigate a possible role for IL-11 in the mechanism of action of IVIg, we first examined the ability of IVIg to ameliorate ITP in IL-11Rα -/-knock-out mice. Using these mice, we found that neither ITP induction nor its amelioration by IVIg depends upon the IL-11 receptor, as the IL-11Rα -/-C57BL/6J knock-out mice responded similarly to IVIg treatment as the C57BL/6J WT littermate mice (Fig. 3a) . However, it was a surprise to us, given that IL-11 plays an important role in megakaryopoiesis/thrombopoiesis [48] [49] [50] [51] , that these knock-out mice had such high platelet numbers (Fig. 3a) . As this may have been due to some redundancy in this cytokine family 52, we looked further at whether rhIL-11 could replace IVIg to ameliorate ITP. We found that platelet numbers increased following rhIL-11 treatment alone, and that this was statistically significant (P ≤ 0·0081) (Fig. 3b ). Finally, we tested IVIg in combination with neutralizing antibody to IL-11. We showed that C57BL/6J mice with ITP administered anti-IL-11 in parallel with IVIg only achieved an approximately 50% increase in platelet counts compared to WT mice given IVIg alone. This 50% reduction in the IVIg response in the presence of neutralizing anti-IL-11 was statistically significant (P ≤ 0·0001) (Fig. 3c) .
Discussion
We have reported previously that the serum levels of IL-4, GM-CSF and IL-11 are elevated significantly in both BALB/cJ and C57BL/6J mice with ITP following IVIg treatment 41, and as IVIg could ameliorate ITP in both these mouse models we asked whether these cytokines may play a role in the mechanism of action of IVIg. We conclude that neither ITP induction nor its amelioration by IVIg depends upon IL-4 (or basophils) or GM-CSF ( Figs. 1 and 2) . Results for IL-11, however, did not rule out a possible role for this cytokine conclusively in the mechanism of IVIg amelioration of experimental ITP.
It has been reported previously that the mechanism of IVIg action in ITP does not require IL-4 when using IL-4 or a common cytokine gamma chain knock-out mouse 40. This contrasts with previous reports that indicate IL-4 as a critical cytokine in the mechanism of IVIg action and that this cytokine is produced by basophils [35, 36] . In our previous work [41] , we observed significantly elevated production of IL-4 in two mouse strains that respond to IVIg treatment; thus, we sought to resolve the controversy of a role for IL-4 by using an IL-4R knock-out mouse and to evaluate the role of basophils in our ITP mouse model. Not unexpectedly, our results with basophil depletion indicated clearly that basophils do not play a role in the mechanism of action of IVIg in ITP (Fig. 1b) . These results mirror previous studies in two different arthritis mouse models, where basophil depletion had no effect on the ability of IVIg to ameliorate the arthritis [28] . Our results with IL-4R knock-out mice indicate clearly that this cytokine also does not play a role in the mechanism of action of IVIg (Fig. 1c) , which confirms previous work [40] and is contrary to other investigators' proposed model [34] [35] [36] .
To our knowledge, we are the first group to investigate a possible role of GM-CSF in the mechanism of action of IVIg. We looked at GM-CSF based on our previous work that showed that GM-CSF was elevated significantly in both BALB/cJ and C57BL/6J mice given IVIg [40] . Using GM-CSF knock-out mice we did not see any differences of ability of IVIg to ameliorate ITP in either the knockout or WT mice, thus ruling out GM-CSF as having a role in the mechanism of action of IVIg (Fig. 2) .
We became interested in a possible role for IL-11 in the mechanism of action of IVIg when we observed that mice with or without ITP produce very high amounts of IL-11 when administered IVIg [41, 46, 47] . Recently, as a small part of another study, we have looked at IL-11 production in 60 patients receiving 2 g/kg of IVIg for various conditions. In this cohort, we have seen that 43 of 60 (72%) patients showed an increase in IL-11 24 hours after IVIg treatment, six of 60 (10%) patients had a higher expression of IL-11 prior to IVIg treatment and 11 of 60 (18%) showed no difference in IL-11 pre-or post-IVIg treatment. Thus, production of IL-11 appears to be a common feature of both murines and humans when given immunomodulatory doses of IVIg. This has piqued our interest in a possible role for IL-11 in the mechanism of action of IVIg [47] .
IL-11 is a pleotropic cytokine belonging to the IL-6 family of cytokines, which includes IL-6 and leukaemia inhibitory factor (LIF), among others [53] . IL-11 has been suggested to play an important role in immunity; however, its role is poorly defined [48] . IL-11 has been described as an inflammatory molecule and an anti-inflammatory molecule [48] . Importantly, IL-11 seems to play a critical role in thrombopoiesis, as it is required for optimal megakaryopoiesis along with thrombopoietin [49] [50] [51] 54] . Indeed, previous work has shown that IVIg treatment in a mouse model of ITP resulted in an increase in young, newly produced, reticulated platelets, and this was proposed as a possible mechanism of IVIg action to ameliorate ITP in this mouse model [43] . It is probable that this increase in platelet production resulted from the induction of IL-11 upon IVIg treatment [47] . Increased thrombopoiesis has been shown to occur in ITP patients receiving IVIg therapy [55, 56] . In our current work, it appears that a role for IL-11 is plausible, because we show that platelet counts decreased by ~50% when a neutralizing anti-IL-11 was used in conjunction with IVIg (Fig. 3c) . Furthermore, there was a significant increase in platelet numbers (50% increase) when using rhIL-11 in place of IVIg (Fig. 3b) . These two findings suggest that IL-11 induced by IVIg treatment plays some role in the mechanism of action of IVIg to ameliorate ITP.
A significant caveat to the conclusion that IL-11 is important for the mechanism of IVIg amelioration of ITP is our finding that mice deficient in IL-11 receptor, IL-11Rα -/-, did not show any differences in amelioration between knock-out and WT littermates (Fig. 3a) . Given the role for IL-11 in megakaryopoiesis/thrombopoiesis [49] [50] [51] 54] , we were surprised to see that these mice had normal to higher platelet counts than WT littermates (Fig. 3a) . We fully expected these mice to have lower platelet numbers unless there may be redundancy within this cytokine family. Indeed, redundancy in the IL-11Rα -/-mouse has been speculated previously to explain a lack of an overt haematological phenotype in these animals [52] . It is intriguing to speculate that IL-6 and/or LIF have replaced the role of IL-11 in this knock-out mouse. It has been proposed that both IL-6 and LIF can be thrombopoietic cytokines [57] . This potential redundancy could explain why IVIg was still capable of ameliorating the platelet deficit in this knock-out mouse, by inducing another thrombopoietic cytokine such as LIF.
In summary, our results confirm that IL-4 or basophils are not involved in the mechanism of action of IVIg in the amelioration of ITP, nor is GM-CSF involved. However, a role for IL-11 cannot be ruled out with certainty, and further studies are necessary to determine if IL-11 may be involved in the mechanism of effect of IVIg.
